Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT03373357
Other study ID # RBM-PAP- 2007/19
Secondary ID
Status Active, not recruiting
Phase N/A
First received December 4, 2017
Last updated December 8, 2017
Start date September 9, 2008
Est. completion date November 30, 2019

Study information

Verified date December 2017
Source Centre Hospitalier Universitaire de Pointe-a-Pitre
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The MAPA is the reference method to estimate the PA during the SAHOS. The MAPA can be recommended over 48 hours: indeed, the PA falls at the beginning of every apnea then increases gradually up to a pressif peak arising at the time of the ventilatoire resumption. These variations arise under the influence of 4 stimulus: the désaturation in O2, the rise of the PaCO2, the increase of the respiratory effort and the microawakening of the end of apnea who are at the origin of a sympathetic stimulation.

Consequently a better diagnostic approach of the HTA (confirmation of a resistant HTA, an identification of the masked HTA and the patients " not dipper " by the MAPA), the identification of the SAHOS, and a better coverage) of the associated cardiovascular risk factors are essential and establish a stake in public health.

To investigator's knowledge, no datum or study on the association HTA-SAHOS and its consequences was until then realized in the French overseas departments.


Description:

In Guadeloupe, data on the relationships between arterial hypertension and obstructive sleep apnea are unavailable. The aim of this study was: to assess the frequency of hypertension and non-dipper pattern evaluated by 48-hour ambulatory blood pressure monitoring in an adult population identified obstructive sleep apnea/non-obstructive sleep apnea during overnight polygraphy ; to determine the cardio-metabolic factors associated with obstructive sleep apnea.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 220
Est. completion date November 30, 2019
Est. primary completion date November 19, 2014
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Patient suspected of SAHOS;

- Patient or third-party responsible for receiving information on the study and who signed informed consent ;

- Patient age over 18 years; Patient living in Guadeloupe.

Exclusion Criteria:

- Patient non-affiliated to the social security scheme ;

- Patient with obstructive bronchopneumopathy, neuro-muscular pathology,

- central and mixed SAS, cardiac arrhythmia,

- systemic and chronic inflammatory syndrome ; -

- Pregnant and lactating patient ;

- patient in emergency.

Study Design


Intervention

Other:
Patient not SAHOS
Phone consultation in 1 month, 3mois, then every 6 months, and an annual visit. Cardiovascular events arisen during the duration of the study Modifications of the lifestyle: alcohol, physical activity Weight Clinical measure of the PA Clinical examination The collection of the cardiovascular events arisen during the duration of the study will be realized for all the inclusive patients
Patient SAHOS sailed by the ventilation in PPC and not sailed
Questionnaire of subjective evaluation of diurnal slumber: scale of Epworth and search for appearance of at least 2 of the following symptoms: sleep not salvage dealer, night-breathlessnesses, multiple awakenings, fatigue, disordersconfusions, nycturie, snore. Questionnaire of evaluation of the global quality of life of the SAHOS Appearance of new cardiovascular risk factors Cardiovascular events arisen during the duration of the study Modification of the current treatments Modifications of the lifestyle: alcohol, physical activity Weight Clinical measure of the PA Clinical examination The collection of the cardiovascular events arisen during the duration of the study will be realized for all the inclusive patients

Locations

Country Name City State
Guadeloupe Hospital University Center of Pointe-à-Pitre Pointe-à-Pitre

Sponsors (1)

Lead Sponsor Collaborator
Centre Hospitalier Universitaire de Pointe-a-Pitre

Country where clinical trial is conducted

Guadeloupe, 

Outcome

Type Measure Description Time frame Safety issue
Primary the frequency of hypertension The primary outcome measure the frequency of hypertension and non-dipper pattern evaluated by 48-hour ambulatory blood pressure monitoring in an adult population identified obstructive sleep apnea/non-obstructive sleep apnea during overnight polygraphy. At the of the enrollment period, an average of 3 years", etc.).
Secondary The cardio-metabolic factors All the enrolled patients will be followed during 5 years and particularly concerning:
the appearance of new risk cardiovascular factors
the advent of cardiovascular events
"through study completion, an average of 8 years"
See also
  Status Clinical Trial Phase
Recruiting NCT05438446 - Effect of Renal Denervation on Stress, Hypertension and Anxiety Management Phase 2
Completed NCT03932721 - EXpanded Combination of Evolocumab Plus Empagliflozin on Diabetes: EXCEED-BHS3 Trial Phase 4
Recruiting NCT05942729 - Etiological DiagnOsis of caRdiac Diseases Based on echoCardiograpHIc Images and Clinical Data.